Evidence mapPaperPMID 39464707Full record

ReviewFrontiers in oncology2024

Innovative strategies in genitourinary cancer: the role of oncolytic viruses.

Jie Zhang, Kepu Liu, Zheng Zhu, Shihao Shang, Di Wei, Yu Zheng, Lei Zhang, Ying Liang, Dongen Ju, Jianlin Yuan

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jie ZhangCollege of Life Sciences, Northwest University, Xi'an, Shaanxi, China.
Kepu LiuDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Zheng ZhuDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Shihao ShangDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Di WeiDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Yu ZhengDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Lei ZhangDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Ying LiangPrecision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Dongen JuDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Jianlin YuanDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urinary tumors pose a significant health threat because of their high prevalence and recurrence rates. Despite the availability of various treatment options, many patients poorly respond to traditional therapies, highlighting the urgent need for alternative approaches. Oncolytic viruses are promising therapeutic agents. These viruses exploit the unique characteristics of cancer cells to specifically target and destroy them, thereby triggering potent antitumor immune responses. This review delves into recent advancements and future prospects of oncolytic viruses, focusing on their application in renal, bladder, and prostate cancers. By discussing practical implications and the potential of different viruses, including the cowpox virus, adenovirus, measles virus, coxsackievirus, and reovirus, we pave the way for further exploration and refinement of this exciting field.

Indexed as

bladder canceroncolytic virusprostate cancerrenal cancertherapytumor

Identifiers

PMID39464707
PMCPMC11502293

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.